Conversations with CEI13 Helmi 2025

The Role of Opioid Treatment Programs in Hepatitis C Care: A Path to Elimination

Between 2010 and 2022 (the latest year for which data are available), 194,375 New Yorkers were diagnosed with hepatitis C (HCV) and of those, 53% (103,213 individuals) are known to have cleared their infection either through treatment or spontaneously. This statistic is worth celebrating, but also highlights the ongoing need for action – the goal outlined in New York State’s Hepatitis C Elimination Plan is to reach 80% by 2030. Furthermore, people who inject drugs are disproportionally affected by HCV – in 2022, 48% of newly reported cases of acute HCV in New York indicated injection drug use as a risk factor. And, when analyzing cases with known risk factors, that figure rose to 81% of newly reported acute cases indicating injection drug use. Providing HCV treatment in opioid treatment program (OTP)s is an innovative and necessary strategy to curb the ongoing epidemic and achieve statewide goals for elimination.

This episode features Abigail Hunter, MPH, MSN, FNP-BC, sharing her experience providing HCV treatment at an OTP and recommendations for listeners interested in integrating treatment into clinical services. Related Content:

CEI Training “Hepatitis C and Injection Drug Use” - https://ceitraining.org/courses/1148
VOCAL-NY: https://www.vocal-ny.org/
Respectful, Equitable Access to Comprehensive Healthcare (REACH) Program at Mount Sinai: https://www.mountsinai.org/care/primary-care/upper-east-side/ima/reach
New York State Department of Health AIDS Institute guideline for the treatment of chronic hepatitis C virus infection in Adults: https://www.hivguidelines.org/hepatitis-care/hcv-treatment/
Taylor, LE. (2020), Colocalization in Hepatitis C Virus Infection Care: The Role of Opioid Agonist Therapy Clinics. Clinical Liver Disease, 16:12-15. https://doi.org/10.1002/cld.921
Addiction Technology Transfer Center Guide to Integrating HCV Services into Opioid Treatment Programs: https://attcnetwork.org/sites/default/files/2020-07/Guide%20to%20Integrating%20HCV%20Services%20into%20Opioid%20Treatment%20-%20July%2024-1.pdf
New York State Hepatitis C Elimination Plan: https://www.health.ny.gov/diseases/communicable/hepatitis/hepatitis_c/docs/hepatitis_c_elimination_plan.pdf
New York State Hepatitis C Dashboard: https://hcvdashboardny.org/
CEI toll free line for NYS providers: 866-637-2342
https://ceitraining.org/

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(63)

Introducing Point-of-Care Testing for Hepatitis C

New York State’s Hepatitis C Dashboard shows that in 2023, 4,783 people were newly diagnosed with HCV in the state, an 8% decrease from 2022. Incidence also decreased, with the rate of new HCV infecti...

14 Touko 21min

Cannabis and Pregnancy

Based on data from 2023-24, roughly 23% of New Yorkers aged 21 or older reported cannabis use in the past 12 months. Although men generally have a higher prevalence of use than women, recent studies s...

20 Huhti 22min

CROI 2026 – Live from Denver: What You Need to Know

Conference on Retroviruses and Opportunistic Infections (CROI) 2026 took place from February 22 to 25 in Denver, Colorado. CROI is an annual scientific meeting devoted to the understanding, prevention...

7 Huhti 15min

Misconceptions about Contraception

Host Dr. Erica Bostick from the University of Rochester Medical Center Division of Adolescent Medicine chats with Dr. Stacy Sun, a double board-certified physician in obstetrics and gynecology and com...

12 Maalis 33min

What “The 72-Hour Rule” Update Means for New York State

Effective February 19, 2026, New York State law permits clinicians to dispense up to 72 hours (equivalent to a 3-day supply) of controlled substances, such as methadone and buprenorphine, for the mana...

17 Helmi 19min

Two New Treatments for Gonorrhea; one is available now!

In this episode of the Conversations with CEI, infectious disease specialist Dr. Steven Fine delves into groundbreaking advancements in the treatment of urogenital gonorrhea. The episode highlights th...

12 Tammi 15min

PrEParing for Lenacapavir Implementation in Your Clinic: Early Lessons Learned

On June 18, 2025, the FDA approved Yeztugo, the brand name for subcutaneous lenacapavir, a prescription medication used for the pre-exposure prophylaxis of HIV. Subcutaneous lenacapavir is administer...

20 Marras 202528min

Keeping an Eye on STIs – Have You Heard of TMVII?

This month, host Dr. Marguerite Urban chats with Dr. Jason Zucker, an adult and pediatric infectious diseases physician at Columbia University and the assistant medical director of the New York City H...

13 Marras 202518min